XML 81 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Tables)
 12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
Condensed Quarterly Income Statement
The following tables provide unaudited consolidated quarterly financial data for 2019 and 2018 (in thousands, except per share data):
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Total revenues
$
75,804

 
$
78,109

 
$
84,131

 
$
89,707

Gross profit
57,327

 
53,819

 
63,026

 
46,386

Operating expenses (1)
175,024

 
169,662

 
81,050

 
240,329

Net loss from continuing operations
$
(122,084
)
 
$
(120,827
)
 
$
(23,617
)
 
$
(199,928
)
Net income (loss) from discontinued operations
$
—

 
$
—

 
$
—

 
$
—

Net loss
$
(122,084
)
 
$
(120,827
)
 
$
(23,617
)
 
$
(199,928
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(3.54
)
 
$
(3.57
)
 
$
(0.70
)
 
$
(5.89
)
Income (loss) from discontinued operations
—

 
—

 
—

 
—

Total
$
(3.54
)
 
$
(3.57
)
 
$
(0.70
)
 
$
(5.89
)
 
March 31, 2018
 
June 30, 2018
 
September 30, 2018
 
December 31, 2018
Total revenues
$
117,387

 
$
146,254

 
$
122,238

 
$
88,122

Gross profit
53,475

 
69,478

 
75,749

 
59,406

Operating expenses (2)
104,239

 
27,591

 
95,084

 
78,241

Net loss from continuing operations
$
(58,098
)
 
$
(25,817
)
 
$
(64,678
)
 
$
(20,746
)
Net income (loss) from discontinued operations
$
3,856

 
$
5,736

 
$
95,517

 
$
(1,531
)
Net (loss) income
$
(54,242
)
 
$
(20,081
)
 
$
30,839

 
$
(22,277
)
 
 
 
 
 
 
 
 
Basic and diluted earnings per share:
 
 
 
 
 
 
 
Loss from continuing operations
$
(1.70
)
 
$
(0.75
)
 
$
(1.88
)
 
$
(0.60
)
Income (loss) from discontinued operations
0.11

 
0.17

 
2.77

 
(0.04
)
Total
$
(1.59
)
 
$
(0.58
)
 
$
0.89

 
$
(0.64
)
The sum of quarterly earnings per share totals differ from annual earnings per share totals due to rounding.

(1) 
Operating expenses for the first quarter of 2019 include $74.9 million relating to IPR&D acquired through the Perosphere acquisition and $7.4 million relating to the restructuring expenses for the consolidation of the women’s health and maternal health sales forces. Operating expenses for the second quarter of 2019 include $77.4 million of impairment charges relating to the Makena base technology intangible asset. Operating expenses for the fourth quarter of 2019 include $155.0 million of impairment charges relating to the Makena auto-injector, Intrarosa and Vyleesi asset groups.

(2) 
Operating expenses for the second quarter of 2018 include the reversal of $49.8 million relating to the fair value of a contingent consideration liability that was no longer expected to be paid.